Skip to search formSkip to main contentSkip to account menu

BMS184476

Known as: beta-(Benzoylamino)-a-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H, BMS 184476, beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H 
A 7-methylthiomethyl ether derivative of paclitaxel with antineoplastic activity. BMS-184476 binds to and stabilizes the resulting microtubules… 
National Institutes of Health

Related topics

Related topics

1 relation
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
BMS 184476 shows “remarkable activity” in previously-treated NSCLC
  • 2005
  • Corpus ID: 195143117
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
Head and neck squamous cell carcinoma cell lines are highly sensitive to the new taxanes, BMS-184476, BMS-188797, in vitro.
BACKGROUND The development of synthetic taxanes targets at increasing solubility of the drug, improved clinical efficacy and… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Review
2003
Review
2003
BMS-184476 Bristol-Myers Squibb.
BMS-184476 is a taxane analog under development by Bristol-Myers Squibb for the potential treatment of solid tumors. By February… 
Review
2002
Review
2002
[New taxanes and epothilone derivatives in clinical trials].
This review describes the experimental and clinical properties of new taxanes and epothilones. Six new taxanes are currently in… 
2002
2002
Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies 1
Purpose: The study was designed to establish the maximum administered dose and maximum tolerated dose (MTD) of BMS-184476, an… 
2001
2001
BMS-184476 demonstrates antitumour activity
  • 2001
  • Corpus ID: 195133111
1999
1999
Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
1999
1999
Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)